Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment

Clinical Cancer Research

Volumn 16, Issue 23, 2010, Pages 5908-5913

  D'Antonio, Katherine B ^a   Schultz, Lucianna ^a   Albadine, Roula ^a   Mondul, Alison M ^b   Platz, Elizabeth A ^a,b,c   Netto, George J ^a,c   Getzenberg, Robert H ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE RICH PROTEIN 61; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; RECURRENCE RISK; TISSUE MICROARRAY;

ADENOCARCINOMA; CASE-CONTROL STUDIES; COHORT STUDIES; CYSTEINE-RICH PROTEIN 61; DOWN-REGULATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650356981     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1200     Document Type: Article

References (19)

1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
2. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
3. Jemal A, Center MM, Ward E, Thun MJ. Cancer occurrence. Methods Mol Biol 2009;471:3-29.
4. Chen Y, Du X. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem 2007;100:1337-45.
5. Planque N, Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 2003;3:15.
6. Chen CC, Young JL, Monzon RI, Chen N, Todorovic V, Lau LF. Cytotoxicity of TNFalpha is regulated by integrin-mediated matrix signaling. EMBO J 2007;26:1257-67.
7. Chen NS, Leu J, Todorovic V, Lam SC, Lau LF. Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for proangiogenic activities in vascular endothelial cells. J Biol Chem 2004;279:44166-76. (Pubitemid 39390724)
8. Menendez JA, Vellon L, Mehmi I, Teng PK, Griggs DW, Lupu R. A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene 2005;24:761-79.
9. Lin MT, Chang CC, Lin BR, Yang HY, Chu CY, Wu MH, et al. Elevated expression of Cyr61 enhances peritoneal dissemination of gastric cancer cells through integrin alpha2beta1. J Biol Chem 2007;282: 34594-604.
10. Bleau AM, Planque N, Perbal B. CCN proteins and cancer: two to tango. Front Biosci 2005;10: 998-1009.
11. Chen PP, Li WJ, Wang Y, Zhao S, Zhao S, Li DY, Feng LY, et al. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One 2007;2:e534.
12. Feng P, Wang B, Ren EC. Cyr61/CCN1 is a tumor suppressor in human hepatocellular carcinoma and involved in DNA damage response. Int J Biochem Cell Biol 2008;40:98-109.
13. Holloway SE, Beck AW, Girard L, Jaber MR, Barnett CC Jr, Brekken RA, et al. Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg 2005;200:371-7.
14. Pilarsky CP, Schmidt U, Eissrich C, Stade J, Froschermaier SE, Haase M, et al. Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 1998;36:85-91.
15. Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A 2002;99:7598-603. (Pubitemid 34568737)
16. Sakamoto S, Yokoyama M, Aoki M, Suzuki K, Kakehi Y, Saito Y. Induction and function of CYR61 (CCN1) in prostatic stromal and epithelial cells: CYR61 is required for prostatic cell proliferation. Prostate 2004;61:305-17.
17. Sun ZJ, Wang Y, Cai Z, Chen PP, Tong XJ, Xie D. Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells. Br J Cancer 2008;99:1656-67.
18. D'Antonio KB, Toubaji A, Albadine R, Mondul AM, Platz EA, Netto GJ, et al. Expression of the extracellular matrix associated protein Cyr61 is linked with the development of prostate cancer. J Urol 2010;183:1604-10.
19. Kononen J, Bubendorf L, Kallioniemi A, B€arlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-947. (Pubitemid 28331029)